QIBA FDG-PET/CT Biomarker Committee (BC) Update Call
23 January 2015 at 9 AM CT (GMT-6)
DRAFT Call Summary

In attendance:
- John Sunderland, PhD (Co-chair)
- Adriaan Lammertsma, PhD
- Pierre Tervé, MS
- Joe Koudelik
- Scott Wollenweber, PhD (Co-chair)
- Martin Lodge, PhD
- Huseyin Tore, MD
- Julie Lisiecki
- Christopher Buckley, PhD
- Lawrence (Larry) MacDonald, PhD
- Timothy Turkington, PhD
- Anthony Lammertsma, PhD
- Pierre Tervé, MS
- Joe Koudelik
- Ming-Kai Chen, MD, PhD
- Amy Perkins, PhD
- Jean-Luc Vanderheyden, PhD
- Paul Kinahan, PhD, FIEE
- Sandra Sanabria, PhD
- Dewen Yang, MD, PhD
- Brian Zimmerman, PhD
- Norman Foster, MD
- Eric Perlman, MD
- Richard Wahl, MD
- Howard Higley, PhD
- John Seibyl, MD
- Jeffrey Yap, PhD
- Paul Kinahan, PhD, FIEE
- Anne Smith, PhD

RSNA

Call Schedule
- The FDG-PET Biomarker Committee meetings will be reduced to once a month, allowing more time for other QIBA NM groups to meet

Single-Photon Emission Computed Tomography (SPECT) (Dr. Wahl)
- A preliminary call for the SPECT Task Force with invited recruits will be held on February 6th, along with FDG-PET BC members

QIBA FDG-PET Profile Field Testing Project Update (Dr. Turkington)
- Weekly t-cons are held with the task force team, and a compliance checklist for Phase I is being developed
- Clinical physicist consultants have been recruited to expedite Phase II of Profile field testing
- Up to 5 additional volunteer sites are welcome to participate, though no more funding is available
  - Action item: Dr. Kinahan to draft letter for the co-chairs to use on QIBA letterhead
- Actual field testing of the checklist and collecting data suggested, moving beyond the initial assessment of real-world functionality
- Field test planning to be added to next agenda for continuing discussion

QIBA Organizational Changes Overview (Dr. Sunderland)
- The QIBA Coordinating Committees (CC) will oversee the BC, respective to their related modalities.
- CC will meet quarterly and will vote on document release (e.g., Profiles, Protocols, etc.), and focus on compliance issues and future planning.
- Another QIBA committee will be formed to handle issues regarding process, and will most likely be referred to as the “Profile Changes and Documentation Committee”
- Documentation for vendors will be an important focus to aid in marketing the Profiles, and also, Digital Reference Objects, or DROs.
- A Profile “stability guarantee” is being considered to avoid frequent revisions, similarly to DICOM
  - It is preferred to refer to a document as a dated edition, e.g., QIBA FDG-PET Profile 2015, rather than “version 1.1.1,” etc.
- Vendors, i.e., engineers, want a stationary guide of specific tasks that can be implemented and tested
  - In addition, Profiles and protocols must have tools for vendor marketing teams in order to communicate the importance of any significant changes effectively for efficient manufacturing
  - Checklists to communicate technical detail in a succinct manner are highly desirable, organized from most important to least important
- The model used by the Association of Electrical Equipment and Medical Imaging Manufacturers, (NEMA), was also recommended as a reference for Profile authors
  - NEMA standards, (vendor-driven), are updated every 5 years
- Dr. Eikman suggested publishing the FDG Profile on a journal website for greater exposure
UPICT Update (Drs. Yap, Sunderland)

- Dr. Graham circulated a summary document of the UPICT Protocol to authors
  - Suggestions were incorporated and the document was submitted to the *Journal of Nuclear Medicine*
  - It is likely that the document will need additional review to address editorial comments received

QIBA PET Amyloid Phantom (Dr. Sunderland)

- The team is working to design a physical phantom in parallel to a DRO for a complete brain phantom with amyloid distribution
  - Trying to locate and evaluate good datasets for this project is challenging
  - Dr. Kinahan recommended a database of 150 patients with high-quality MRIs which are downloadable; however, IRB approval will be required
  - Cross-modality partners in this area are Dr. Barboriak and Mr. Tervé

Proposed Call Schedule (Fridays, 9 am CT):

- **January 30:** PET Amyloid Biomarker Ctte
- **February 6:** SPECT Task Force with FDG-PET Biomarker Ctte
- **February 13:** PET Amyloid Biomarker Ctte
- **February 20:** FDG-PET Biomarker Ctte or SPECT Task Force
- **February 27:** PET Amyloid Biomarker Ctte